In a report released yesterday, Balaji Prasad from Barclays maintained a Hold rating on Amneal Pharmaceuticals Inc (AMRX – Research Report), with a price target of $5. The company’s shares closed yesterday at $4.05, close to its 52-week low of $4.02.
According to TipRanks.com, Prasad is a 2-star analyst with an average return of 0.0% and a 47.6% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Teva Pharmaceutical Industries Limited, Osmotica Pharmaceuticals Plc, and Bausch Health Companies Inc.
Amneal Pharmaceuticals Inc has an analyst consensus of Moderate Buy, with a price target consensus of $14.25, a 251.9% upside from current levels. In a report released yesterday, RBC Capital also downgraded the stock to Hold with a $6 price target.
Based on Amneal Pharmaceuticals Inc’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $47.88 million. In comparison, last year the company had a GAAP net loss of $19.1 million.
Based on the recent corporate insider activity of 23 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of AMRX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Amneal Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development, manufacture, market and distribution of generic pharmaceutical products. It operates through the Generics and Specialty segments.